Although a recent study reported no difference in serum TRAIL levels between MS patients and healthy controls, comparative analysis of patients reporting different clinical forms and activity phases of the disease showed that TRAIL is significantly reduced during relapse in relapsing-remitting MS patients [97]. This evidence concerns the gene TNFSF10 and myeloid sarcoma.